| Purchase price allocation | |
| US$’000 | |
| Consideration: | |
| Cash paid to shareholders | |
| 621 | |
| Shares issued to shareholders | |
| 372 | |
| Deferred consideration | |
| 244 | |
| Total Consideration | |
| 1,237 |
| Fair value of net assets acquired: | |
| Cash and cash equivalents | |
| 12 | |
| Trade and other receivables | |
| 12 | |
| Trade and other payables | |
| (2) | |
| Borrowings | |
| (42) | |
| Intangible assets identified on acquisition: | |
| Customer Relationship | |
| 150 | |
| Regulatory asset | |
| 507 | |
| Deferred tax liability on intangible assets | |
| (164) | |
| Total net assets | |
| 473 | |
| Goodwill | |
| 764 | |
| Total | |
| 1,237 |
| Company | ||||
| Country of | ||||
| registration or | ||||
| incorporation | Registered office | Principal activity | ||
| Percentage of ordinary | ||||
| shares held | ||||
| HeiQ Materials AG | Switzerland | |||
| Rütistrasse 12, 8952 | ||||
| Schlieren Zurich | ||||
| Development, | ||||
| production and sale of | ||||
| chemicals | ||||
| 100% | ||||
| HeiQ ChemTex Inc. | United States | |||
| 2725 Armentrout Dr, | ||||
| Concord, NC 28025 | ||||
| Development, | ||||
| production and sale of | ||||
| chemicals | ||||
| 100% | ||||
| HeiQ Pty Ltd | Australia | |||
| Level 20/181 William Street, | ||||
| Melbourne, VIC 3000 | ||||
| Research and | ||||
| development | ||||
| 100% | ||||
| HeiQ GrapheneX AG | Switzerland | |||
| Rütistrasse 12, 8952 | ||||
| Schlieren Zurich | ||||
| Research and | ||||
| development | ||||
| 100% | ||||
| HeiQ Company Limited | Taiwan | |||
| No. 14 & 16, Ln. 50, Wufu | ||||
| 1st Rd. Luzhu District, | ||||
| Taoyuan City 33850 | ||||
| Distribution | 100% | |||
| HX Company Limited | Taiwan | |||
| No. 14 & 16, Ln. 50, Wufu | ||||
| 1st Rd. Luzhu District, | ||||
| Taoyuan City 33850 | ||||
| Trading and | ||||
| production | ||||
| 66.7% | ||||
| HeiQ Iberia Unipessoal | ||||
| Lda | ||||
| Portugal | ||||
| Rua Engº Frederico Ulrich, nº | ||||
| 2650, 4470-605 Maia | ||||
| Sales agency and | ||||
| internal services | ||||
| company | ||||
| 100% |
| Company | ||||
| Country of | ||||
| registration or | ||||
| incorporation | Registered office | Principal activity | ||
| Percentage of ordinary | ||||
| shares held | ||||
| Chrisal NV | Belgium | |||
| Priester Daensstraat 9, | ||||
| 3920 Lommel, Belgium | ||||
| Biotechnology | 71% | |||
| HeiQ RAS AG | Germany | |||
| Rudolf Vogt Straße 8-10, | ||||
| 93053 Regensburg | ||||
| Materials innovation | 100% | |||
| HeiQ Regulatory GmbH | Germany | |||
| Rudolf Vogt Straße 8-10, | ||||
| 93053 Regensburg | ||||
| Materials innovation | 100% | |||
| HeiQ (China) Material | ||||
| Tech LTD | ||||
| China | ||||
| Room 2501, Xuhui | ||||
| Commercial Mansion, No. | ||||
| 168 Yude Road, Shanghai | ||||
| Distribution | 100% | |||
| Life Material Technologies | ||||
| Limited | ||||
| Hong Kong | ||||
| Alexandra House, 6th Floor, | ||||
| 16-20 Chater Road, Central | ||||
| Materials technology | 100% | |||
| Life Natural Limited | Hong Kong | |||
| Alexandra House, 6th Floor, | ||||
| 16-20 Chater Road, Central | ||||
| Inactive | 100% | |||
| LMT Holding Limited | Thailand | |||
| 222 Lumpini Building 2, 247 | ||||
| Rajdamri Road | ||||
| Lumpini, Phatumwan, | ||||
| Bangkok 10330 | ||||
| Holding | 96.45% | |||
| Life Material Technologies | ||||
| Limited | ||||
| Thailand | ||||
| 222 Lumpini Building 2, 247 | ||||
| Rajdamri Road | ||||
| Lumpini, Phatumwan, | ||||
| Bangkok 10330 | ||||
| Trading | 99.995% | |||
| HeiQ AeoniQ GmbH | Austria | |||
| Industriestrasse 35, 3130 | ||||
| Herzogenburg | ||||
| Materials Innovation | 96% | |||
| Chem-Tex Laboratories | ||||
| Inc. | ||||
| United States | ||||
| 2725 Armentrout Dr, | ||||
| Concord, NC 28025 | ||||
| Chemical production | ||||
| site | ||||
| 100% | ||||
| Beijing HeiQ Material Tech | ||||
| Co., Ltd. | ||||
| China | ||||
| Room 17B9870, Floor 17, | ||||
| 101 Nei, -4 to 33, Building | ||||
| 13, Wangjing Dongyuan | ||||
| Siqu, Chaoyang District, | ||||
| Beijing | ||||
| Inactive/Distribution | 100% | |||
| HeiQ AeoniQ Holding AG | Switzerland | Parkstrasse 1, 5234 Villigen | Holding | 95.95% |
| Tarn-Pure Holdings Ltd | United Kingdom | |||
| Castle Court, 6 Cathedral | ||||
| Road, Cardiff, CF11 9LJ | ||||
| Holding | 100% | |||
| Tarn Pure (IP) Limited | ||||
| United Kingdom | ||||
| Castle Court, 6 Cathedral | ||||
| Road, Cardiff, CF11 9LJ | ||||
| Holder of intellectual | ||||
| property | ||||
| 100% | ||||
| Tarn-Pure AG Ltd. | ||||
| United Kingdom | ||||
| Castle Court, 6 Cathedral | ||||
| Road, Cardiff, CF11 9LJ | ||||
| Trading | 100% | |||
| Tarn-Pure Ireland Limited | Ireland | |||
| C/O Duggan & Power, Odeon | ||||
| House 7, Eyre Square, Co. | ||||
| Galway | ||||
| Trading | 100% | |||
| HeiQ AeoniQ Portugal | Portugal | |||
| Rua Engº Frederico Ulrich, nº | ||||
| 2650, 4470-605 Maia | ||||
| Materials Innovation | 100% |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Revenue by organizational unit | ||
| US$’000 | US$’000 | |
| Advanced Materials | ||
| 50,697 | 38,366 | |
| LifeSciences | ||
| 6,988 | 6,164 | |
| Other activities | ||
| 4,633 | 2,872 | |
| Total revenue | ||
| 62,318 | 47,202 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Revenue by timing of revenue | ||
| US$’000 | US$’000 | |
| Goods transferred at a point in time | ||
| 56,860 | 45,002 | |
| Services | ||
| transferred at a point in time | ||
| 1,914 | 160 | |
| Services transferred over time | ||
| 3,544 | 2,040 | |
| Total revenue | ||
| 62,318 | 47,202 |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Unsatisfied performance obligations | ||
| US$’000 | US$’000 | |
| Exclusivity services | ||
| 1,200 | 2,100 | |
| Research and development services | ||
| 5,087 | 3,750 | |
| Total unsatisfied performance obligations | ||
| 6,287 | 5,850 |
| Advanced Materials | LifeSciences | Other activities | ||||||
| Total | ||||||||
| US$’000 | ||||||||
| Period | ||||||||
| 23/24 | ||||||||
| Year | ||||||||
| 2022 | ||||||||
| Period | ||||||||
| 23/24 | ||||||||
| Year | ||||||||
| 2022 | ||||||||
| Period | ||||||||
| 23/24 | ||||||||
| Year | ||||||||
| 2022 | ||||||||
| Period | ||||||||
| 23/24 | ||||||||
| Year | ||||||||
| 2022 | ||||||||
| Revenue | ||||||||
| 50,697 | 38,366 | 6,988 | 6,164 | 4,633 | 2,672 | 62,318 | 47,202 | |
| Operating profits (loss) | ||||||||
| (4,391) | (14,347) | (1,385) | (5,537) | (13,206) | (9,361) | (18,982) | (29,245) | |
| Financial result | ||||||||
| (1,441) | (590) | |||||||
| Loss before taxation | ||||||||
| (20,423) | (29,835) | |||||||
| Taxation | ||||||||
| (915) | 21 | |||||||
| Loss after taxation | ||||||||
| (21,338) | (29,814) | |||||||
| Depreciation and amortization | ||||||||
| Property, plant and equipment | ||||||||
| 1,200 | 362 | 453 | 335 | 662 | 585 | 2,315 | 1,282 | |
| Right-of use assets | ||||||||
| 383 | 165 | 218 | 145 | 972 | 628 | 1,573 | 938 | |
| Intangible Assets | ||||||||
| 1,512 | 773 | 837 | 550 | 889 | 112 | 3,238 | 1,435 | |
| Impairment loss | ||||||||
| Property, plant and equipment | ||||||||
| - | - | - | 730 | - | - | - | 730 | |
| Intangible Assets | ||||||||
| 323 | 8,247 | - | 2,402 | - | 1,002 | 323 | 11,651 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Revenue by region | ||
| US$’000 | US$’000 | |
| North & South America | ||
| 26,726 | 20,425 | |
| Asia | ||
| 18,911 | 13,376 | |
| Europe | ||
| 16,228 | 13,109 | |
| Others | ||
| 453 | 293 | |
| Total revenue | ||
| 62,318 | 47,202 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Non -current assets by region | ||
| US$’000 | US$’000 | |
| Europe | ||
| 30,379 | 22,290 | |
| Asia | ||
| 2,226 | 8,102 | |
| North & South America | ||
| 7,318 | 7,734 | |
| Others | ||
| 176 | 612 | |
| Total non-current assets | ||
| 40,099 | 38,738 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Cost of sales | ||
| US$’000 | US$’000 | |
| Material expenses | ||
| 30,086 | 20,942 | |
| Personnel expenses | ||
| 4,682 | 2,830 | |
| Depreciation of property, plant and equipment | ||
| 892 | 652 | |
| Inventory allowance increase (reduction) | ||
| (427) | 4,912 | |
| Other costs of sales | ||
| 4,252 | 4,409 | |
| Total cost of sales | ||
| 39,485 | 33,745 |
| Period ended | Year ended | |
| June 30, | December | |
| 31, | ||
| 2024 | 2022 | |
| Other income | ||
| US$’000 | US$’000 | |
| Gain on disposal of property plant and equipment | ||
| 23 | 21 | |
| Gain on earnout consideration payable (Note 5g) | ||
| 138 | - | |
| Foreign exchange gains | ||
| 121 | 3,539 | |
| Fair value gain on derivative liabilities (Note 38) | ||
| 367 | 371 | |
| Income from out-of-court settlement | ||
| 2,750 | - | |
| Other income | ||
| 1,243 | 901 | |
| Total other income | ||
| 4,642 | 4,832 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| Selling and general administration expenses | ||
| 2024 | ||
| US$’000 | ||
| 2022 | ||
| US$’000 | ||
| Personnel expenses | ||
| 19,324 | 14,977 | |
| Depreciation of property, plant and equipment | ||
| 1,423 | 630 | |
| Amortization of intangible assets | ||
| 3,238 | 1,435 | |
| Depreciation of right-of | ||
| -use assets | ||
| 1,573 | 938 | |
| Net credit losses on financial assets and contract assets | ||
| 1,025 | 85 | |
| Other | ||
| 17,186 | 12,904 | |
| Total selling and general administration expense | ||
| 43,769 | 30,969 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Auditor’s remuneration | ||
| US$’000 | US$’000 | |
| Audit of Group performed by Group Auditor | ||
| 443 | 1,180* | |
| Audit of subsidiaries performed by local auditors | 77 | 122 |
| Total fees for audit services | ||
| 520 | 1,302 | |
| Audit related assurance services | ||
| - | - | |
| Other assurance services | ||
| - | - | |
| Total auditor remuneration | ||
| - | - |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Personnel expenses | ||
| US$’000 | US$’000 | |
| Wages & salaries | ||
| 21,273 | 15,274 | |
| Social security & other payroll taxes | ||
| 2,249 | 1,685 | |
| Pension costs | ||
| 306 | 710 | |
| Share-based payments | ||
| 178 | 138 | |
| Total personnel expenses | ||
| 24,006 | 17,807 | |
| Reported as cost of sales (Note 9) | ||
| 4,682 | 2,830 | |
| Reported as selling and general administration expense (Note 11) | ||
| 19,324 | 14,977 | |
| Total personnel expenses | ||
| 24,006 | 17,807 | |
| The average monthly number of employees was as follows: | ||
| 194 | ||
| 218 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Other expenses | ||
| US$’000 | US$’000 | |
| Foreign exchange losses | ||
| 343 | 3,050 | |
| Loss on disposal of property, plant and equipment | ||
| 204 | 16 | |
| Transaction costs relating to mergers and acquisitions | ||
| 23 | 50 | |
| Write off intangible assets (Note 18) | ||
| 1,419 | 897 | |
| Other | ||
| 376 | 171 | |
| Total other expenses | ||
| 2,365 | 4,184 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Finance income | ||
| US$’000 | US$’000 | |
| Interest income | ||
| 18 | 5 | |
| Gains on foreign currency transactions | ||
| 157 | 678 | |
| Other | ||
| 27 | - | |
| Total finance income | ||
| 202 | 683 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Finance costs | ||
| US$’000 | US$’000 | |
| Amortization of deferred finance costs – acquisition costs | ||
| 3 | - | |
| Lease finance expense | ||
| 311 | 163 | |
| Interest on borrowings | ||
| 586 | 110 | |
| Bank fees | ||
| 364 | 98 | |
| Loss on foreign currency transactions | ||
| 379 | 902 | |
| Total finance costs | ||
| 1,643 | 1,273 |
| Period ended | ||||
| June 30, 2024 | ||||
| Year ended | ||||
| December 31, 2022 | ||||
| US$’000 | Tax rate % | US$’000 | Tax rate % | |
| Expected tax at average | ||||
| tax rate | ||||
| (3,905) | 20.2% | (6,304) | 21.1% | |
| Increase/(decrease) in tax resulting from: | ||||
| Tax credits | ||||
| 21 | (0.1%) | (340) | 1.1% | |
| Unrecognized tax losses | ||||
| 4,385 | (22.7%) | 3,796 | (12.7%) | |
| Non-deductible expenditure | ||||
| 52 | (0.3%) | 2,586 | (8.7%) | |
| Temporary differences | ||||
| 328 | (1.7%) | 165 | (0.6%) | |
| Other – net | ||||
| 34 | (0.1%) | 76 | (0.1%) | |
| Total income tax expense (income) | ||||
| 915 | (4.7%) | (21) | 0.1% |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Current income tax expense | ||
| US$’000 | US$’000 | |
| Swiss corporate income taxes | ||
| (27) | 58 | |
| United States state and federal taxes | ||
| 455 | 393 | |
| Taiwan corporate income taxes | ||
| 229 | 118 | |
| Belgium corporate income taxes | ||
| 37 | (123) | |
| Germany corporate income taxes | ||
| (24) | 51 | |
| United Kingdom corporate income taxes | ||
| 89 | - | |
| Others | ||
| 1 | 63 | |
| Total current income tax expense | ||
| 760 | 560 | |
| Switzerland | ||
| 518 | 90 | |
| United States | ||
| (38) | (606) | |
| China | ||
| 6 | 117 | |
| Austria | ||
| 3 | 20 | |
| Belgium | ||
| (198) | (136) | |
| Germany | ||
| (91) | (68) | |
| Others | ||
| (45) | 2 | |
| Total deferred income tax expense (income) | ||
| 155 | (581) | |
| Total income tax expense (income) | ||
| 915 | (21) |
| Switzerland | ||
| 518 | 90 | |
| United States | ||
| (38) | (606) | |
| China | ||
| 6 | 117 | |
| Austria | ||
| 3 | 20 | |
| Belgium | ||
| (198) | (136) | |
| Germany | ||
| (91) | (68) | |
| Others | ||
| (45) | 2 | |
| Total deferred income tax expense (income) | ||
| 155 | (581) | |
| Total income tax expense (income) | ||
| 915 | (21) |
| Period ended | Year ended | |
| June 30, | ||
| December 31, | ||
| 2024 | ||
| 2022 | ||
| Items that will not be reclassified subsequently to profit or loss | ||
| US$’000 | US$’000 | |
| Remeasurement of net defined benefit liability | ||
| 42 | (276) | |
| Total income tax recognized in other comprehensive income | ||
| 42 | (276) |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Net tax(assets)/liabilities | ||
| US$’000 | US$’000 | |
| Opening balance – (prepaid taxes) | ||
| (343) | 51 | |
| Assumed on business combinations | ||
| - | - | |
| Assumed on asset acquisition | ||
| - | (32) | |
| Income tax expense for the year | ||
| 760 | 560 | |
| Taxes paid | ||
| (1,023) | (870) | |
| Foreign currency differences | ||
| - | (52) | |
| Net tax (asset)/liability | ||
| (606) | (343) |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Net tax(assets) liabilities | ||
| US$’000 | US$’000 | |
| Prepaid income taxes | ||
| (795) | (657) | |
| Income tax liabilities | ||
| 189 | 314 | |
| Net tax (asset)/liability | ||
| (606) | (343) |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Earnings | ||
| US$’000 | US$’000 | |
| Loss attributable to the ordinary equity holders of the parent entity | ||
| (20,839) | (29,251) |
| Period ended | Year ended | |
| June 30, | December 31, | |
| Number of shares | ||
| 2024 | 2022 | |
| Weighted average number of ordinary shares for the purposes of basic | ||
| earnings per share | ||
| 158,135,830 | ||
| 133,426,953 |
| Goodwill | ||||||
| Internally | ||||||
| developed | ||||||
| assets | ||||||
| Brand names | ||||||
| and customer | ||||||
| relations | ||||||
| Acquired | ||||||
| technologies | ||||||
| Other | ||||||
| intangible | ||||||
| assets | Total | |||||
| Cost | ||||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| As at January 1, 2022 | ||||||
| 21,382 | 3,509 | 4,503 | 3,180 | 2,332 | 34,906 | |
| Additions arising from internal | ||||||
| development | ||||||
| - | 2,165 | - | - | - | 2,165 | |
| Other acquisitions | ||||||
| - | - | - | - | 1,700 | 1,700 | |
| Disposals / write-offs | ||||||
| - | (85) | - | - | (812) | (897) | |
| Currency translation differences | ||||||
| (795) | 5 | (160) | (165) | 14 | (1,101) | |
| As at December 31, 2022 | ||||||
| 20,587 | 5,594 | 4,343 | 3,015 | 3,234 | 36,773 | |
| Business combinations | ||||||
| 764 | - | 150 | - | 507 | 1,421 | |
| Additions arising from internal | ||||||
| development | ||||||
| - | 1,277 | - | - | - | 1,277 | |
| Other acquisitions | ||||||
| - | - | - | - | 150 | 150 | |
| Disposals / write-offs | - | (1,169) | - | - | (1,806) | (2,975) |
| Deconsolidation of subsidiary | ||||||
| (123) | - | - | - | - | (123) | |
| Currency translation differences | ||||||
| 70 | 141 | 14 | 7 | 106 | 338 | |
| As at June 30, 2024 | ||||||
| 21,298 | 5,843 | 4,507 | 3,022 | 2,191 | 36,861 | |
| Amortization and accumulated impairment losses | ||||||
| As at January 1, 2022 | 2,305 | 474 | 602 | 234 | 518 | 4,133 |
| Amortization for the year | ||||||
| - | 198 | 695 | 334 | 208 | 1,435 | |
| Impairment loss | ||||||
| 10,576 | 880 | 73 | - | 122 | 11,651 | |
| Currency translation differences | ||||||
| (750) | 3 | (72) | (45) | (24) | (888) | |
| As at December 31, 2022 | ||||||
| 12,131 | 1,555 | 1,298 | 523 | 824 | 16,331 | |
| Amortization for the year | ||||||
| - | 1,136 | 1,057 | 500 | 545 | 3,238 | |
| Disposals / write-offs | ||||||
| - | (958) | - | - | (599) | (1,557) | |
| Deconsolidation of subsidiary | (123) | - | - | - | - | (123) |
| Impairment loss | ||||||
| - | 323 | - | - | - | 323 | |
| Currency translation differences | ||||||
| 19 | 30 | (46) | (30) | 5 | (22) | |
| As at June 30, 2024 | ||||||
| 12,027 | 2,086 | 2,309 | 993 | 775 | 18,190 | |
| Net book value | ||||||
| As at December 31, 2022 | ||||||
| 8,456 | 4,039 | 3,045 | 2,492 | 2,410 | 20,442 | |
| As at June 30, 2024 | ||||||
| 9,271 | 3,757 | 2,198 | 2,029 | 1,416 | 18,671 |
| Balance | ||||
| acquired | ||||
| Accumulated | ||||
| impairment | ||||
| Currency | ||||
| revaluation | Net book value | |||
| Goodwill | ||||
| US$’000 | US$’000 | US$’000 | US$’000 | |
| ChemTex | ||||
| 3,393 | - | 3,393 | ||
| Chrisal* | ||||
| 6,163 | (3,677) | (291) | 2,195 | |
| RAS (incl. Tarn Pure in 2023/2024)* | ||||
| 7,998 | (4,007) | (308) | 3,683 | |
| Life | ||||
| 5,202 | (5,202) | - | - | |
| MasFabEs** | ||||
| 123 | (123) | - | - | |
| Total goodwill | ||||
| 22,879 | (13,009) | (599) | 9,271 |
| Assumption | ChemTex | Chrisal | RAS |
| Discount factor | 9.3% | 9.8% | 8.3% |
| Perpetual growth rate | 2.09% | 1.96% | 1.96% |
| Compound annual growth rate for the next five years | 5.2% | 36.8% | 15.8% |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Goodwill book value | ||
| US$’000 | US$’000 | |
| ChemTex | ||
| 3,393 | 3,393 | |
| Chrisal* | ||
| 2,195 | 2,189 | |
| RAS (incl. Tarn Pure in 2023/2024)* | ||
| 3,683 | 2,874 | |
| Life | ||
| - | - | |
| Total goodwill book value | ||
| 9,271 | ||
| 8,456 |
| Machinery and | ||||||
| equipment | Motor vehicles | |||||
| Computers and | ||||||
| software | ||||||
| Furniture and | ||||||
| fixtures | ||||||
| Land and | ||||||
| buildings | Total | |||||
| Cost | ||||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| As at January 1, 2022 | ||||||
| 7,288 | 536 | 914 | 474 | 1,523 | 10,735 | |
| Additions | ||||||
| 2,272 | 26 | 197 | 50 | 2,735 | 5,280 | |
| Disposals | ||||||
| (69) | (12) | - | - | - | (81) | |
| Reclassifications | ||||||
| (407) | 59 | - | 348 | - | - | |
| Currency translation differences | ||||||
| (233) | (1) | (21) | (23) | (90) | (368) | |
| As at December 31, 2022 | ||||||
| 8,851 | 608 | 1,090 | 849 | 4,168 | 15,566 | |
| Additions | ||||||
| 1,319 | 113 | 32 | 62 | 5,505 | 7,031 | |
| Disposals | ||||||
| (1,748) | (59) | (748) | (207) | - | (2,762) | |
| Deconsolidation of subsidiary | ||||||
| (1,265) | (30) | (11) | (33) | - | (1,339) | |
| Reclassifications | ||||||
| (37) | - | - | 37 | - | - | |
| Currency translation differences | ||||||
| 76 | 1 | 27 | 10 | (68) | 46 | |
| As at June 30, 2024 | ||||||
| 7,196 | 633 | 390 | 718 | 9,605 | 18,542 | |
| Depreciation and accumulated impairment | ||||||
| losses | ||||||
| As at January 1, 2022 | ||||||
| 2,723 | 330 | 619 | 86 | 112 | 3,870 | |
| Charge for the year | ||||||
| 763 | 90 | 218 | 83 | 128 | 1,282 | |
| Eliminated on disposal | ||||||
| (27) | (5) | - | - | - | (32) | |
| Impairment loss | ||||||
| 730 | - | - | - | - | 730 | |
| Reclassifications | ||||||
| (222) | - | - | 222 | - | - | |
| Currency translation differences | (67) | - | (9) | (3) | (7) | (86) |
| As at December 31, 2022 | ||||||
| 3,900 | 415 | 828 | 388 | 233 | 5,764 | |
| Charge for the year | ||||||
| 1,421 | 114 | 148 | 152 | 480 | 2,315 | |
| Eliminated on disposal | ||||||
| (736) | (35) | (743) | (198) | - | (1,712) | |
| Deconsolidation of subsidiary | ||||||
| (1,210) | (8) | (5) | (8) | - | (1,231) | |
| Reclassifications | ||||||
| 7 | - | (6) | (1) | - | - | |
| Currency translation differences | ||||||
| 67 | 1 | 22 | 7 | (3) | 94 | |
| As at June 30, 2024 | ||||||
| 3,449 | 487 | 244 | 340 | 710 | 5,230 | |
| Net book value | ||||||
| As at December 31, 2022 | ||||||
| 4,951 | 193 | 262 | 461 | 3,935 | 9,802 | |
| As at June 30, 2024 | ||||||
| 3,747 | 146 | 146 | 378 | 8,895 | 13,312 |
| Land and buildings | Motor vehicles | |||
| Machinery and | ||||
| equipment | Total | |||
| Cost | ||||
| US$’000 | US$’000 | US$’000 | US$’000 | |
| As at January 1, 2022 | ||||
| 8,913 | 611 | 341 | 9,865 | |
| Additions | ||||
| 86 | 174 | 1,921 | 2,181 | |
| Disposals due to expiry of lease | ||||
| - | (36) | - | (36) | |
| Disposals due to business combination* | ||||
| (467) | - | - | (467) | |
| Modification to lease terms** | ||||
| (1,199) | - | - | (1,199) | |
| Currency translation differences | ||||
| (381) | (67) | (26) | (474) | |
| As at December 31, 2022 | ||||
| 6,952 | 682 | 2,236 | 9,870 | |
| Additions | ||||
| 860 | 140 | 913 | 1,913 | |
| Disposals due to expiry of lease | ||||
| (475) | (40) | (32) | (547) | |
| Modification to lease terms*** | ||||
| (1,228) | (110) | - | (1,338) | |
| Currency translation differences | ||||
| (58) | 19 | (29) | (68) | |
| As at June 30, 2024 | ||||
| 6,051 | 691 | 3,088 | 9,830 | |
| Depreciation | ||||
| As at January 1, 2022 | ||||
| 1,716 | 109 | 66 | 1,891 | |
| Depreciation for the year | ||||
| 730 | 140 | 68 | 938 | |
| Disposals due to expiry of lease | ||||
| - | (36) | - | (36) | |
| Modification to lease terms** | ||||
| (693) | - | - | (693) | |
| Currency translation differences | ||||
| (34) | (6) | (9) | (49) | |
| As at December 31, 2022 | ||||
| 1,719 | 207 | 125 | 2,051 | |
| Depreciation for the year | ||||
| 1,096 | 232 | 245 | 1,573 | |
| Disposals due to expiry of lease | ||||
| (301) | (25) | (33) | (359) | |
| Modification to lease terms*** | ||||
| (990) | (41) | - | (1,031) | |
| Currency translation differences | ||||
| (134) | (1) | (1) | (136) | |
| As at June 30, 2024 | ||||
| 1,390 | 372 | 336 | 2,098 | |
| Net book value | ||||
| As at December 31, 2022 | ||||
| 5,233 | 475 | 2,111 | 7,819 | |
| As at June 30, 2024 | ||||
| 4,661 | 319 | 2,752 | 7,732 |
| Period ended | ||
| June 30, | ||
| 2024 | ||
| Year ended | ||
| December 31, | ||
| 2022 | ||
| US$’000 | US$’000 | |
| Depreciation expense on right-of-use assets | ||
| 1,573 | 938 | |
| Interest expense on lease liabilities | ||
| 311 | 163 | |
| Expense relating to short-term leases | ||
| 374 | 225 | |
| Expense relating to leases of low value assets | ||
| 51 | 40 | |
| Gain from early disposal and modification of leases | ||
| 33 | 68 |
| Period ended | ||
| June 30, | ||
| 2024 | ||
| Year ended | ||
| December 31, | ||
| 2022 | ||
| US$’000 | US$’000 | |
| Total fixed lease payments | ||
| 1996 | 992 | |
| Gain from early disposal and modification of leases | ||
| (33) | (68) | |
| Interest paid on leases | ||
| 311 | 163 |
| As at | ||
| As at | ||
| June 30, | December 31 | |
| 2024 | 2022 | |
| Other non-current assets | ||
| US$’000 | US$’000 | |
| Deposits | ||
| 72 | ||
| 80 | ||
| Other prepayments | ||
| 7 | ||
| 57 | ||
| Other non-current assets | ||
| 79 | ||
| 137 |
| As at | ||
| As at | ||
| June 30, | December 31 | |
| 2024 | 2022 | |
| Inventories | ||
| US$’000 | US$’000 | |
| Gross inventories | ||
| 12,616 | 18,564 | |
| Allowance for inventories | ||
| (4,360) | (5,396) | |
| Net realizable value | ||
| 8,256 | 13,168 |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Trade receivables | ||
| US$’000 | US$’000 | |
| Not past due | ||
| 2,791 | 2,788 | |
| <30 days | ||
| 2,011 | 520 | |
| 31-60 days | ||
| 671 | 781 | |
| 61-90 days | ||
| 234 | 215 | |
| 91-120 days | ||
| 46 | 180 | |
| >120 days | ||
| 1,782 | 2,407 | |
| Total trade receivables | ||
| 7,535 | 6,891 | |
| Provision for expected credit losses | ||
| (1,280) | (404) | |
| Total trade receivables (net) | ||
| 6,255 | 6,487 |
| Trade receivables – days past due | |||||
| Not past due | 1-60 | 61-120 | >120 days | Total | |
| Expected credit loss | |||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Expected credit loss rate | |||||
| 1% | 1% | 1% | 68% | 17% | |
| Estimated total gross carrying amount at default | |||||
| 2,791 | 2,682 | 280 | 1,782 | 7,535 | |
| Lifetime ECL as at June 30, 2024 | |||||
| 40 | 18 | 2 | 1,220 | 1,280 |
| Trade receivables – days past due | |||||
| Not past due | 1-60 | 61-120 | >120 days | Total | |
| Expected credit loss | |||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Expected credit loss rate | |||||
| 0% | 0% | 0% | 17% | 6% | |
| Estimated total gross carrying amount at default | |||||
| 2,788 | 1,301 | 395 | 2,407 | 6,891 | |
| Lifetime ECL as at December 31, 2022 | |||||
| - | - | - | 404 | 404 |
| Individually | |||
| assessed | |||
| Collectively | |||
| assessed | Total | ||
| Expected credit losses | |||
| US$’000 | US$’000 | US$’000 | |
| Balance as at January 1, 2022 | |||
| 278 | 46 | 324 | |
| Net remeasurement of loss allowance | |||
| 172 | (6) | 166 | |
| Amounts written off | |||
| (81) | - | (81) | |
| Foreign exchange gains and losses | |||
| (4) | (1) | (5) | |
| Balance as at December 31, 2022 | |||
| 365 | 39 | 404 | |
| Net remeasurement of loss allowance | |||
| 878 | 85 | 963 | |
| Amounts written off | |||
| (97) | - | (97) | |
| Foreign exchange gains and losses | |||
| 12 | (2) | 10 | |
| Balance as at June 30, 2024 | |||
| 1,158 | 122 | 1,280 |
| Period ended | ||
| June 30, | ||
| 2024 | ||
| US$’000 | ||
| Year ended | ||
| December 31, | ||
| 2022 | ||
| US$’000 | ||
| Origination of new trade receivables net of those settled, as well as increase in days past | ||
| due up to 120 days | ||
| 878 | 172 | |
| Write-off of receivables older than 120 days | ||
| (97) | (81) |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Other receivables and prepayments | ||
| US$’000 | US$’000 | |
| Contract assets | ||
| 83 | 115 | |
| Receivables from tax authorities | ||
| 1,804 | 1,864 | |
| Prepayments | ||
| 769 | 1,023 | |
| Other receivables | ||
| 269 | 1,260 | |
| Total other receivables and prepayments | ||
| 2,925 | 4,262 |
| As at | |||
| June 30, | |||
| As at | |||
| December 31, | |||
| As at | |||
| January 1, | |||
| 2024 | 2022 | 2022 | |
| Contract assets | |||
| US$’000 | US$’000 | US$’000 | |
| Research and development services | |||
| 83 | 65 | 80 | |
| Take-or-pay services | |||
| - | - | 170 | |
| Exclusivity services | |||
| - | 50 | - | |
| Total contract assets | |||
| 83 | 115 | 250 | |
| Current assets | |||
| 83 | |||
| 115 | 250 | ||
| Non-current assets | |||
| - | |||
| - | - | ||
| Total contract assets | |||
| - | |||
| 115 | 250 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| Expected credit loss | ||
| US$’000 | US$’000 | |
| Expected credit loss rate | ||
| 0% | 0% | |
| Estimated total gross carrying amount at default | ||
| 83 | 115 | |
| Lifetime ECL | ||
| - | - | |
| Net carrying amount | ||
| 83 | 115 |
| Note | Number of shares | Share capital | Share premium | Totals | |
| No. | US$’000 | US$’000 | US$’000 | ||
| Balance as of January 1, 2022 | |||||
| 130,583,536 | 51,523 | 144,191 | 195,714 | ||
| Issue of shares to vendors of Life Materials | |||||
| 347,552 | 141 | 471 | 612 | ||
| Issue of shares as deferred consideration | |||||
| 3,461,615 | 1,359 | 2,921 | 4,280 | ||
| Issue of shares to Advisory Board and others | |||||
| 164,721 | 60 | 175 | 235 | ||
| Issue of shares ChemTex Labs | |||||
| 2,176,884 | 795 | 1,177 | 1,972 | ||
| Issue of shares Chrisal | |||||
| 3,348,164 | 1,223 | 1,838 | 3,061 | ||
| Balance as at December 31, 2022 | |||||
| 140,082,472 | 55,101 | 150,773 | 205,874 | ||
| Issue of shares Tarn Pure (a) | |||||
| 455,435 | 160 | 212 | 372 | ||
| Issue of shares from fundraise (b) | |||||
| 28,000,000 | 1,752 | 1,296 | 3,048 | ||
| Balance as at June 30, 2024 | |||||
| 168,537,907 | 57,013 | 152,281 | 209,294 |
| Period ended June 30, 2024 | ||||
| Year ended December 31, 2022 | ||||
| Number of | ||||
| options | ||||
| Weighted average | ||||
| exercise price (£) | ||||
| Number of | ||||
| options | ||||
| Weighted average | ||||
| exercise price (£) | ||||
| Outstanding at beginning of period/year | ||||
| 11,525,911 | 1.05 | |||
| 8,707,65 | 8 1.14 | |||
| Granted during the period/year | ||||
| 10,300,000 | 0.09 | |||
| 3,349,12 | 5 0.83 | |||
| Forfeited during the period/year | ||||
| (2,364,362) | 1.06 | |||
| (530,872) | 1.12 | |||
| Lapsed during the period/year | ||||
| (3,783,496) | 1.23 | |||
| Vested during the period/year | ||||
| (1,046,504) | 1.23 | |||
| - | - | |||
| Exercised during the period/year | ||||
| - | - | |||
| - | - | |||
| Expired during the period/year | ||||
| - | - | - | - | |
| Outstanding at the end of the period | ||||
| 14,631,549 | 0.31 | |||
| 11,525,911 | 1.05 | |||
| Exercisable at the end of the period | 1,046,504 | |||
| 1.23 | ||||
| - | ||||
| - |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Model used | ||
| Monte Carlo | Black Scholes | |
| Weighted average share price (£) | ||
| 0.0860 | 0.817 | |
| Weighted average exercise price (£) | ||
| 0.0898 | 0.834 | |
| Expected volatility | ||
| 65.0% | 69.3%/70.3%* | |
| Expected life | ||
| 2.7 years | ||
| 2.6 /2.3 | ||
| Risk-free rate | ||
| 4.32% | 1.90%/4.38%* | |
| Expected dividend yields | ||
| 0% | 0% | |
| Share price hurdle | ||
| £0.3250 | n/a |
| Share- based | ||||||
| payment | ||||||
| reserve | ||||||
| Merger | ||||||
| reserve | ||||||
| Currency | ||||||
| translation | ||||||
| reserve | Other reserve | |||||
| Total Other | ||||||
| reserves | ||||||
| Note | ||||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | ||
| Balance at January 1, 2022 | ||||||
| 474 | (126,912) | 387 | (1,144) | (127,195) | ||
| Other comprehensive (loss)/income | ||||||
| - | - | (1,914) | 1,104 | (810) | ||
| Total comprehensive (loss)/income for | ||||||
| the year | ||||||
| - | - | (1,914) | 1,104 | (810) | ||
| Share-based payment charges | ||||||
| 2 | ||||||
| 7 | ||||||
| (12) | - | - | - | (12) | ||
| Transactions with owners | ||||||
| (12) | - | - | - | (12) | ||
| Balance at December 31, 2022 | ||||||
| 462 | (126,912) | (1,527) | (40) | (128,017) | ||
| Other comprehensive (loss)/income | ||||||
| - | - | 466 | (136) | 330 | ||
| Total comprehensive (loss)/income for | ||||||
| the year | ||||||
| - | - | 466 | (136) | 330 | ||
| Share-based payment | ||||||
| charges/(reversal) | ||||||
| 2 | ||||||
| 7 | ||||||
| (51) | - | - | - | (51) | ||
| Transactions with owners | ||||||
| (51) | - | - | - | (51) | ||
| Balance at June 30, 2024 | ||||||
| 411 | (126,912) | (1,061) | (176) | (127,738) |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| Net benefit obligations | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Fair value of plan assets | ||
| 7,245 | ||
| 9,616 | ||
| Defined benefit obligations | ||
| (8,094) | (10,568) | |
| Funded status (net liability) | ||
| (849) | (952) | |
| Duration (years) | ||
| 15.8 | ||
| 13.8 | ||
| Expected benefits payable in following year | ||
| (351) | ||
| (389) |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Development of obligations and assets | ||
| US$’000 | US$’000 | |
| Present value of funded obligations, beginning of period/year | ||
| (10,568) | (13,003) | |
| Employer service cost | ||
| (571) | (571) | |
| Employee contributions | ||
| (452) | (352) | |
| Past service cost | ||
| 341 | - | |
| Curtailments/Settlements | ||
| 148 | - | |
| Interest cost | ||
| (302) | (45) | |
| Benefits paid/(refunded) | ||
| 4,309 | 522 | |
| Actuarial (loss)/gain on benefit obligation | ||
| (636) | 2,562 | |
| Currency (loss)/gain | ||
| (363) | 319 | |
| Present value of funded obligations, end of period/year | ||
| (8,094) | (10,568) | |
| Defined benefit obligation participants | ||
| (6,746) | (10,568) | |
| Defined benefit obligation pensioners | ||
| (1,348) | - | |
| Present value of funded obligations, end of period/year | ||
| (8,094) | (10,568) | |
| Fair value of plan assets, beginning of period/year | ||
| 9,616 | 10,858 | |
| Expected return on plan assets | ||
| 273 | 37 | |
| Employer’s contributions | ||
| 448 | 352 | |
| Employees’ contributions | ||
| 452 | 352 | |
| Benefits (paid)/refunded | ||
| (4,309) | (522) | |
| Admin expense | ||
| (28) | (21) | |
| Actuarial (loss)/gain on plan assets | ||
| 458 | (1,182) | |
| Currency gain/(loss) | ||
| 335 | (258) | |
| Fair value of plan assets, end of period/year | ||
| 7,245 | 9,616 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| Movements in net liability recognized in statement of financial position: | ||
| 2024 | ||
| US$’000 | ||
| 2022 | ||
| US$’000 | ||
| Net liability, beginning of year | ||
| (952) | (2,146) | |
| Employer service cost | ||
| (571) | (571) | |
| Interest cost | ||
| (302) | (45) | |
| Expected return on plan assets | ||
| 273 | 37 | |
| Admin expense | ||
| (28) | (21) | |
| Past service cost recognized in period/year | ||
| 341 | - | |
| Curtailment, settlement, plan amendment gain (loss) | ||
| 148 | - | |
| Employer’s contributions (following year expected contributions) | ||
| 448 | 352 | |
| Prepaid (accrued) pension cost: | ||
| (311) | 247 | |
| - operating income (expense) | ||
| 339 | (240) | |
| - finance expense | ||
| (28) | (7) |
| Total gains recognized within other comprehensive income | ||
| (178) | 1,380 | |
| Currency loss | ||
| (28) | 62 | |
| Net liability, end of period/year | ||
| (849) | (952) | |
| Expected employer's cash contributions for following period/year | ||
| 264 | 360 |
| Period ended | Year ended | |
| June 30, | December 31, | |
| Amounts recognized in profit and loss | ||
| 2024 | ||
| US$’000 | ||
| 2022 | ||
| US$’000 | ||
| Employer service cost | ||
| (571) | (571) | |
| Past service cost recognized in period/year | ||
| 341 | - | |
| Interest cost | ||
| (302) | (45) | |
| Expected return on plan assets | ||
| 273 | 37 | |
| Admin expense | ||
| (28) | (21) | |
| Curtailment, settlement, plan amendment gain (loss) | ||
| 150 | - | |
| Components of defined benefit costs recognized in profit or loss | ||
| (137) | (600) |
| Period ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Amounts recognized in other comprehensive income | ||
| US$’000 | US$’000 | |
| Actuarial gains/(losses) arising from plan experience | ||
| 212 | 193 | |
| Actuarial (losses)/gains arising from demographic assumptions | ||
| - | (23) | |
| Actuarial gains arising from financial assumptions | ||
| (848) | 2,392 | |
| Re-measurement of defined benefit obligations | ||
| (636) | 2,562 | |
| Re-measurement of assets | ||
| 458 | (1,182) | |
| Deferred tax asset derecognized / (recognized) | ||
| 42 | (276) | |
| Total recognized in OCI | ||
| (136) | 1,104 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| Asset allocation | ||
| 2024 | 2022 | |
| Cash | ||
| 1.2% | 2.8% | |
| Bonds | ||
| 30.2% | 29.1% | |
| Equities | ||
| 34.4% | 33.2% | |
| Property (incl. mortgages) | ||
| 28.8% | 31.3% | |
| Other | ||
| 5.4% | 3.6% | |
| Total | ||
| 100.0% | 100.0% |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| The principal assumptions | ||
| 2024 | 2022 | |
| Discount rate | ||
| 1.50% | 2.25% | |
| Interest credit rate | ||
| 2.00% | 2.25% | |
| Average future salary increases | ||
| 1.50% | 2.50% | |
| Future pension increases | ||
| 0.00% | 0.00% | |
| Mortality tables used | ||
| BVG 2020 GT | ||
| BVG 2020 GT | ||
| Average retirement age | ||
| 65/65 | ||
| 65/65 |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| Impact on defined benefit obligation | ||
| 2024 | 2022 | |
| Discount rate + 0.25% | ||
| (308) | (323) | |
| Discount rate – 0.25% | ||
| 329 | 343 | |
| Salary increase + 0.25% | ||
| 44 | 44 | |
| Salary increase – 0.25% | ||
| (43) | (43) | |
| Pension increase + 0.25% | ||
| 165 | 167 | |
| Pension decrease – 0.25% (not lower than 0%) | ||
| - | - |
| As at | ||
| June 30, | ||
| 2024 | ||
| As at | ||
| December 31, | ||
| 2022 | ||
| Lease liabilities | ||
| US$’000 | US$’000 | |
| Not later than one year | ||
| 1,151 | 1,301 | |
| Later than one year and not later than five years | ||
| 3,398 | 3,813 | |
| Later than five years | ||
| 3,271 | 3,387 | |
| Total minimum lease payments | ||
| 7,820 | 8,501 | |
| Less: Future finance charges | ||
| (539) | (679) | |
| Present value of minimum lease payments | ||
| 7,281 | 7,822 | |
| Current liability | ||
| 997 | 1,264 | |
| Non-current liability | ||
| 6,284 | 6,558 | |
| 7,281 | 7,822 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| Borrowings | ||
| US$’000 | US$’000 | |
| Unsecured bank loans | ||
| 9,973 | 3,573 | |
| Secured bank loans | ||
| 793 | 628 | |
| Loans from related parties | ||
| 443 | - | |
| Loans from non-controlling interest | ||
| - | 137 | |
| Total borrowings | ||
| 11,209 | 4,338 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Not later than one year | ||
| 9,380 | 2,893 | |
| Later than one year but less than five years | ||
| 884 | 1,029 | |
| After more than five years | ||
| 945 | 416 | |
| Total borrowings | ||
| 11,209 | 4,338 |
| As at June 30, 2024 | As at December 31, 2022 | ||||||
| Description | Currency | Repayment date | |||||
| Principal | |||||||
| US$’000 | |||||||
| Interest rate | |||||||
| Principal | |||||||
| US$’000 | |||||||
| Interest rate | |||||||
| Credit facility | |||||||
| CHF | August 2024 | ||||||
| 550 | 7.10% | - | - | ||||
| Credit facility | |||||||
| CHF | September 2024 | ||||||
| 1,100 | 5.45% | - | - | ||||
| Credit facility | |||||||
| CHF | July 2024 | ||||||
| 5,829 | 4.44% | 2,574 | 2.20% | ||||
| Credit facility | |||||||
| CHF | July 2024 | ||||||
| 550 | 4.40% | - | - | ||||
| Credit facility | |||||||
| EUR | July 2024 | ||||||
| 415 | 6.82% | - | - | ||||
| Various bank loans | |||||||
| 1) | |||||||
| EUR | 1-10 years | ||||||
| 1,504 | 3,04% | 999 | 2.21% | ||||
| Bank loan | |||||||
| GBP | May 2026 | ||||||
| 25 | 2.50% | - | - | ||||
| Outstanding at the end of the year | |||||||
| 9,973 | 3,573 |
| Pension fund | |||||
| obligations | |||||
| Tax losses | Share-based | ||||
| payments | |||||
| Temporary | |||||
| differences | |||||
| Total | |||||
| Deferred tax | |||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Balance at January 1, 2022 | 429 | 178 | 85 | (1,686) | (994) |
| Charge/(credit) | |||||
| to profit or loss | |||||
| 49 | (150) | 1 | 681 | 581 | |
| Credit | |||||
| to other comprehensive income | |||||
| (276) | - | - | - | (276) | |
| Foreign currency differences | |||||
| (12) | (28) | 5 | 9 | (26) | |
| Balance as at December 31, 2022 | |||||
| 190 | - | 91 | (996) | (715) | |
| Charge/(credit) | |||||
| to profit or loss | |||||
| (457) | - | (87) | 389 | (155) | |
| Charge to other comprehensive income | |||||
| 42 | - | - | - | 42 | |
| Arising from business combinations | |||||
| - | - | - | (164) | (164) | |
| Foreign currency differences | |||||
| 20 | - | (4) | 8 | 24 | |
| Balance as at June 30, 2024 | |||||
| (205) | - | - | (763) | (968) |
| Year ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Deferred tax | ||
| Deferred tax assets | ||
| 305 | 538 | |
| Deferred tax liabilities | ||
| (1,273) | (1,253) | |
| Net deferred tax assets (liabilities) | ||
| (968) | (715) |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Defined benefit obligation IAS 19 Switzerland (Note 29) | ||
| 849 | 952 | |
| Defined benefit obligation IAS 19 Thailand (Note 29) | ||
| 134 | 134 | |
| Contract liabilities | ||
| 4,758 | 3,614 | |
| Deferred grant income | ||
| - | 14 | |
| Total other non-current liabilities | ||
| 5,741 | 4,714 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Trade payables | ||
| 3,706 | 3,321 | |
| Payables to tax authorities | ||
| 315 | 375 | |
| Other payables | ||
| 1,940 | 1,626 | |
| Total trade and other payables | ||
| 5,961 | 5,322 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Costs of goods sold | ||
| 837 | 875 | |
| Personnel expenses | 1,202 | 1,737 |
| Other operating expenses | ||
| 1,027 | 2,366 | |
| Total accrued liabilities | ||
| 3,066 | 4,978 |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Contract liabilities | ||
| 1,700 | 1,176 | |
| Prepayments for unshipped goods | ||
| 120 | 94 | |
| Deferred grant income | ||
| 92 | 15 | |
| Total deferred revenue | ||
| 1,912 | 1,285 |
| As at | |||
| June 30, | |||
| As at | |||
| December 31, | |||
| As at | |||
| January 1, | |||
| 2024 | 2022 | 2022 | |
| US$’000 | US$’000 | US$’000 | |
| Exclusivity agreements | |||
| 2,107 | 1,832 | - | |
| Research and development services | |||
| 4,351 | 2,958 | 1,000 | |
| Total contract liabilities | |||
| 6,458 | 4,790 | 1,000 | |
| Current liabilities (Note 36) | |||
| 1,700 | 1,176 | 1,000 | |
| Non-current liabilities (Note 33) | |||
| 4,758 | 3,614 | - | |
| Total contract liabilities | |||
| 6,458 | 4,790 | 1,000 |
| Period ended | ||
| June 30, | ||
| Year ended | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Exclusivity agreements | ||
| 785 | ||
| - | ||
| Research and development services | ||
| 905 | ||
| - | ||
| Total revenue recognized from contract liabilities | ||
| 1,690 | ||
| - |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Deferred consideration in relation to acquisitions | ||
| 169 | 92 | |
| Call option derivative liability | ||
| 333 | 686 | |
| Other current liabilities | ||
| 502 | 778 |
| ChemTex | RAS AG | Life | Tarn Pure | Total | |
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| As at January 1, 2022 | |||||
| 279 | 3,152 | 2,652 | - | 6,083 | |
| Foreign exchange revaluation | |||||
| - | (277) | - | - | (277) | |
| Consideration settled in cash | |||||
| (187) | - | (1,400) | - | (1,587) | |
| Consideration settled in shares | |||||
| - | (2,875) | (1,252) | - | (4,127) | |
| As at December 31, 2022 | |||||
| 92 | - | - | - | 92 | |
| Additions from acquisition as per Note 5a | |||||
| - | - | - | 244 | 244 | |
| Consideration settled in cash | |||||
| - | - | - | (180) | (180) | |
| Amortization of fair value discount | |||||
| - | - | - | 3 | 3 | |
| Foreign exchange revaluation | |||||
| - | - | - | 10 | 10 | |
| As at June 30, 2024 | |||||
| 92 | - | - | 77 | 169 |
| Weighted average share price (€) | |
| 2,285.71 | |
| Weighted average exercise price (€) | |
| 2,500.00 | |
| Expected volatility | |
| 22.5% | |
| Expected life | |
| 0.5 year | |
| Risk-free rate | |
| 1.0% | |
| Expected dividend yield | |
| 0% |
| As at | ||
| June 30, | ||
| As at | ||
| December 31, | ||
| Provisions | ||
| 2024 | 2022 | |
| US$’000 | US$’000 | |
| Legal/Compliance provision | ||
| - | 339 | |
| Total provisions | ||
| - | 339 |
| Current liability | ||
| - | 339 | |
| Non-current liability | ||
| - | - | |
| Total provisions | ||
| - | 339 |
| Legal/Compliance | ||
| provision | Total | |
| US$’000 | US$’000 | |
| Provisions | ||
| Balance at January 1, 2022 | ||
| - | - | |
| Additional provision in the year | ||
| 339 | 339 | |
| Utilization of provision | ||
| - | - | |
| Exchange difference | ||
| - | - | |
| Balance as at December 31, 2022 | ||
| 339 | 339 | |
| Additional provision in the year | ||
| - | - | |
| Utilization of provision | ||
| (339) | (339) | |
| Exchange difference | ||
| - | - | |
| Balance as at June 30, 2024 | ||
| - | - |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Financial instruments | ||
| US$’000 | US$’000 | |
| Cash and cash equivalents | ||
| 5,027 | 8,488 | |
| Trade receivables | ||
| 6,255 | 6,487 | |
| Accrued income and other receivables | ||
| 2,156 | 3,239 | |
| Trade and other payables | ||
| (5,961) | (5,322) | |
| Accrued liabilities | ||
| (3,066) | (4,978) | |
| Deferred consideration | ||
| (169) | (92) | |
| Call option derivative liability | ||
| (333) | (686) | |
| Borrowings held at amortized cost | ||
| (11,209) | (4,338) | |
| Lease liabilities held at present value of lease payments | ||
| (7,281) | (7,823) | |
| Total financial instruments | ||
| (14,581) | (5,025) |
| Functional currency | ||||||
| AUD | EUR | GBP | US$ | Others | Total | |
| As at June 30, 2024 | ||||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Financial assets denominated in $ | ||||||
| - | 153 | 3 | 1,386 | (4) | 1,538 | |
| Financial liabilities denominated in $ | ||||||
| - | (163) | - | 407 | - | 244 | |
| Net foreign currency exposure | ||||||
| - | (10) | 3 | 1,793 | (4) | 1,782 |
| Functional currency | ||||||
| AUD | EUR | GBP | US$ | Others | Total | |
| As at December 31, 2022 | ||||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Financial assets denominated in $ | ||||||
| 19 | 92 | 206 | 6,771 | 3 | 7,091 | |
| Financial liabilities denominated in $ | ||||||
| - | - | - | - | - | - | |
| Net foreign currency exposure | ||||||
| 19 | 92 | 206 | 6,771 | 3 | 7,091 |
| AUD | EUR | GBP | US$ | Others | |
| As at June 30, 2024 | |||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Effect on net assets: | |||||
| Strengthened by 10% | |||||
| - | (1) | - | 179 | 178 | |
| Weakened by 10% | |||||
| - | 1- | - | (179) | (178) |
| AUD | EUR | GBP | US$ | Others | |
| As at December 31, 2022 | |||||
| US$’000 | US$’000 | US$’000 | US$’000 | US$’000 | |
| Effect on net assets: | |||||
| Strengthened by 10% | |||||
| 2 | 9 | 21 | 677 | - | |
| Weakened by 10% | |||||
| (2) | (9) | (21) | (677) | - |
| Less than | ||||
| 1 year | ||||
| 2 to 5 | ||||
| years | ||||
| > 5 | ||||
| years | Total | |||
| As at June 30, 2024 | ||||
| US$’000 | US$’000 | US$’000 | US$’000 | |
| Trade and other payables | ||||
| 5,961 | - | - | 5,961 | |
| Borrowings held at amortized cost | ||||
| 9,380 | 884 | 945 | 11,209 | |
| Leases (gross cash flows) | ||||
| 1,151 | 3,398 | 3,271 | 7,820 | |
| Other liabilities | ||||
| 3,255 | - | - | 3,255 | |
| Financing facilities | ||||
| 19,747 | 4,282 | 4,216 | 28,245 |
| Less than | ||||
| 1 year | ||||
| 2 to 5 | ||||
| years | ||||
| > 5 | ||||
| years | Total | |||
| As at December 31, 2022 | ||||
| US$’000 | US$’000 | US$’000 | US$’000 | |
| Trade and other payables | ||||
| 5,322 | - | - | 5,322 | |
| Borrowings held at amortized cost | ||||
| 2,893 | 1,029 | 416 | 4,338 | |
| Leases (gross cash flows) | ||||
| 1,302 | 3,813 | 3,387 | 8,502 | |
| Other liabilities | ||||
| 5,290 | - | - | 5,290 | |
| Financing facilities | ||||
| 14,807 | 4,842 | 3,803 | 23,452 |
| As at | ||
| June 30, | ||
| 2024 | ||
| As at | ||
| December 31, | ||
| 2022 | ||
| Unsecured bank overdraft facility | ||
| US$’000 | US$’000 | |
| Amount used | ||
| 8,935 | 2,790 | |
| Amount unused | ||
| 414 | 6,861 | |
| Total | ||
| 9,349 | 9,651 |
| As at | ||
| As at | ||
| June 30, | December 31, | |
| 2024 | 2022 | |
| Equity ratio | ||
| US$’000 | US$’000 | |
| Equity | ||
| 25,428 | 40,339 | |
| Total equity and liabilities | ||
| 62,562 | 71,143 | |
| Equity ratio | ||
| 41% | 57% |
| Note | |||
| As at | |||
| June 30, | |||
| As at | |||
| December 31, | |||
| 2024 | 2022 | ||
| Gains and losses on disposal of assets | |||
| US$’000 | US$’000 | ||
| Gain on disposal of property, plant and equipment | |||
| 10 | |||
| (23) | (21) | ||
| Loss on disposal of property, plant and equipment | |||
| 13 | |||
| 204 | 16 | ||
| Net loss (gain) on disposal of assets | |||
| 181 | (5) |
| Liabilities arising from financing activities | |||
| Leases | |||
| US$’000 | |||
| Borrowings | |||
| US$’000 | |||
| Total | |||
| US$’000 | |||
| Balance at January 1, 2022 | |||
| 8,114 | 2,762 | 10,876 | |
| Cash flows | |||
| (992) | 2,561 | 1,569 | |
| New lease agreements | |||
| 2,181 | - | 2,181 | |
| Revaluation of lease agreements | |||
| (574) | - | (574) | |
| Disposal due to acquisitions | |||
| (490) | - | (490) | |
| Loans waived by creditors | |||
| - | (764) | (764) | |
| Exchange differences | |||
| (416) | (221) | (637) | |
| Balance at December 31, 2022 | |||
| 7,823 | 4,338 | 12,161 | |
| Cash flows | |||
| (1,996) | 7,300 | 5,304 | |
| New lease agreements | |||
| 1,601 | - | 1,601 | |
| Revaluation of lease agreements | |||
| (213) | - | (213) | |
| Derecognized following deconsolidation of subsidiary | |||
| - | (304) | (304) | |
| Exchange differences | |||
| 66 | (125) | (59) | |
| Balance at June 30, 2024 | |||
| 7,281 | 11,209 | 18,490 |
| Period ended June 30, 2024 | |||||
| Opening balances | |||||
| Assumed on | |||||
| acquisition of | |||||
| assets | |||||
| Deconsolidation of | |||||
| subsidiary | |||||
| Change in | |||||
| balance | |||||
| Closing balances | |||||
| US$’000 | US$’000 | US$’000 | US$’000 | ||
| US$’000 | |||||
| Inventories | |||||
| 13,168 | 13 | (5) | (4,920) | ||
| 8,256 | |||||
| Trade receivables | |||||
| 6,487 | 2 | (18) | (216) | ||
| 6,255 | |||||
| Other receivables and prepayments | |||||
| 4,262 | 10 | 900 | (2,247) | ||
| 2,925 | |||||
| Trade and other receivables and prepayments | |||||
| 10,749 | 12 | 882 | (2,463) | ||
| 9,180 | |||||
| Trade and other payables | |||||
| 5,322 | 2 | (315) | 952 | ||
| 5,961 | |||||
| Accrued liabilities | |||||
| 4,978 | - | - | (1,912) | ||
| 3,066 | |||||
| Deferred revenue incl. non-current contract | |||||
| liabilities | |||||
| 4,913 | - | (460) | 2,217 | ||
| 6,670 | |||||
| Trade and other payables, accrued liabilities and | |||||
| deferred revenue | |||||
| 15,213 | 2 | (775) | 1,257 | ||
| 15,697 |
| Year ended December 31, 2022 | ||||
| Opening balances | ||||
| Assumed on | ||||
| acquisition of | ||||
| assets | ||||
| Change in | ||||
| balance | ||||
| Closing balances | ||||
| US$’000 | US$’000 | US$’000 | ||
| US$’000 | ||||
| Inventories | ||||
| 13,770 | - | (602) | ||
| 13,168 | ||||
| Trade receivables | ||||
| 14,656 | - | (8,169) | 6,487 | |
| Other receivables and prepayments | ||||
| 3,876 | - | 386 | 4,262 | |
| Trade and other receivables and prepayments | 18,532 | - | (7,783) | 10,749 |
| Trade and other payables | ||||
| 8,271 | - | (2,949) | 5,322 | |
| Accrued liabilities | ||||
| 3,386 | 9 | 1,583 | 4,978 | |
| Deferred revenue incl. non-current contract liabilities | ||||
| 1,004 | - | 3,909 | 4,913 | |
| Trade and other payables, accrued liabilities and deferred revenue | 12,661 | 9 | 2,543 | 15,213 |
| Period ended June 30, 2024 | |
| US$’000 | |
| Consideration payment for acquisition of Tarn Pure | |
| 801 | |
| Cash assumed on acquisition of Tarn Pure | |
| (12) | |
| Net consideration payment for acquisitions of businesses and assets | |
| 789 |
| Year ended December 31, 2022 | |
| US$’000 | |
| Consideration payment for acquisition of Life Materials Technologies Ltd | |
| 1,400 | |
| Consideration payment for acquisition of ChemTex assets | |
| 187 | |
| Net consideration payment for acquisitions of businesses and assets | |
| 1,587 |
| As at | ||
| June 30, | ||
| 2024 | ||
| As at | ||
| December 31, | ||
| 2022 | ||
| Loans due to related parties | ||
| US$’000 | US$’000 | |
| Cortegrande AG, €400,000 (Note 31) | ||
| 443 | - | |
| Loans due to related parties | ||
| 443 | - |
| Year ended | Year ended | |
| June 30, | December 31, | |
| 2024 | 2022 | |
| Remuneration of key management personnel | ||
| US$’000 | US$’000 | |
| Short- | ||
| term employee benefits | ||
| 1,042 | 738 | |
| Post-employment benefits | ||
| 42 | 35 | |
| Cash remuneration of key management personnel | ||
| 1,084 | 773 | |
| Share-based payment expense (income) | 46 | (58) |
| Total remuneration of key management personnel | ||
| 1,130 | 715 |